Study type: In vivo/preclinical · Status: Verified against declared source

Humanin analogue, HNG, inhibits platelet activation and thrombus formation by stabilizing platelet microtubules.

Journal of cellular and molecular medicine · 2020

Study scale: For the platelet microtubule acetylation assay, resting platelets or microtubule depolymerization reagent, nocodazole‐treated platelets after incubation with HNG (10 μM) at 37°C for 10 minutes were fixed in microtubule‐preserving fixative (PHEM) buffer supplemented with 4% PFA (1:1), followed by centrifugation on poly‐L‐lysine‐coated coverslips.

Abstract only: Open source record

Product or molecular entity relationships

Humanin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Pre‐incubated platelets (250 µl, 2 × 108/ml) were stimulated by agonist with stirring.

Scale or participants

For the platelet microtubule acetylation assay, resting platelets or microtubule depolymerization reagent, nocodazole‐treated platelets after incubation with HNG (10 μM) at 37°C for 10 minutes were fixed in microtubule‐preserving fixative (PHEM) buffer supplemented with 4% PFA (1:1), followed by centrifugation on poly‐L‐lysine‐coated coverslips.

Key findings

HNG, a highly potent mutant of the anti‐Alzheimer peptide‐humanin, has been shown to protect against ischaemia‐reperfusion (I/R) injury.

Limitations and uncertainty

HNG, a highly potent mutant of the anti‐Alzheimer peptide‐humanin, has been shown to protect against ischaemia‐reperfusion (I/R) injury.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.